Saptan 15 Overdosage

Antagonism of the arginine vasopressin V₂ receptors in the renal collecting ducts causes an increase in urine water excretion resulting in increased free water clearance, decreased urine osmolality, and increased serum sodium concentrations.
Overdose effects are anticipated to be an extension of adverse effects observed following therapeutic doses (Thirst, dry mouth, asthenia, constipation, polyuria, and hyperglycemia are the most common adverse effects. Pyrexia was reported in Tolvaptan-treated patients during clinical efficacy trials. Severe hepatotoxicity, including development of acute liver failure requiring transplantation, has occurred during clinical trials of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who were being treated with Tolvaptan).
Treatment is symptomatic and supportive. There is no known antidote.
Decontamination is generally not indicated as toxicity is limited (480 mg of Tolvaptan was well tolerated in volunteers). Consider activated charcoal after very large ingestions or if toxic coingestants are involved and the patients is alert and able to protect their airway.
Monitoring of patient: Monitor vital signs, fluid status, serum electrolytes and urine output after significant overdose. Monitor liver enzymes as indicated in symptomatic patients.